NCT04423393 - Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

November 25, 2022

Conditions

Chronic Hepatitis B

Interventions

BIOLOGICAL

VIR-3434

VIR-3434 given by subcutaneous injection or intravenous infusion.

OTHER

Placebo

Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.

Trial Locations (24)

1010

Investigative Site, Auckland

3110

Investigative Site, Tauranga

4130

Investigative Site, Havelock North

6021

Investigative Site, Newtown

30625

Investigative Site, Hanover

45147

Investigative Site, Essen

47392

Investigative Site, Busan

49241

Investigative Site, Busan

55131

Investigative Site, Mainz

60590

Investigative Site, Frankfurt

68167

Investigative Site, Mannheim

89081

Investigative Site, Ulm

169608

Investigative Site, Singapore

529889

Investigative Site, Singapore

04103

Investigative Site, Leipzig

Unknown

Investigative Site, Hong Kong

Investigative Site, Bucharest

02841

Investigative Site, Seoul

03080

Investigative Site, Seoul

05505

Investigative Site, Seoul

06273

Investigative Site, Seoul

B15 2TT

Investigative Site, Birmingham

E1 2EF

Investigative Site, London

M8 5RB

Investigative Site, Manchester

All Listed Sponsors

lead

Vir Biotechnology, Inc.

INDUSTRY